Rare Variant and Epigenomic Analysis in ME/CFS
Duration: 36 months, Funding volume: € 999,169
Predicting the evolution of relapse in Wilms tumour using drug sensitivity profiling and liquid biopsies
Funding volume: € 999,538
Personalized risk assessment for embryonal tumor predisposition
Funding volume: € 999,003
Functional Identification of Response Biomarkers to Advance Precision Oncology in Childhood Cancers
Funding volume: € 999,357
Simultaneous assessment of muscle perfusion and mitochondrial function in ME/CFS
Funding volume: € 40,000
Mechanism-based Reversibility Evaluation and Stratified Endophenotyping of Treatment-response in ME/CFS
Duration: 36 months, Funding volume: € 999,930